UnitedHealthcare Pharmacy
Clinical Pharmacy Programs
Program Number 2025 P 1195-11
Program Prior Authorization/Notification
Medication Nuplazid® (pimavanserin)
P&T Approval Date 7/2016, 7/2017, 8/2018, 8/2019, 10/2019, 11/2020, 11/2021, 12/2022,
1/2024, 3/2025
Effective Date 6/1/2025
1. Background:
Nuplazid (pimavanserin) is an atypical antipsychotic indicated for the treatment of hallucinations and
delusions associated with Parkinson’s disease psychosis. Nuplazid is not approved for the treatment
of patients with dementia who experience psychosis unless their hallucinations and delusions are
related to Parkinson’s disease.
2. Coverage Criteriaa:
A. Initial Authorization
1. Nuplazid will be approved based on the following criteria:
a. Diagnosis of Parkinson’s disease
Authorization will be issued for 12 months.
B. Reauthorization
1. Nuplazid will be approved based on the following criterion:
a. Documentation of positive clinical response to Nuplazid therapy
Authorization will be issued for 12 months.
a State mandates may apply. Any federal regulatory requirements and the member specific benefit
plan coverage may also impact coverage criteria. Other policies and utilization management
3. Additional Clinical Rules:
• Notwithstanding Coverage Criteria, UnitedHealthcare may approve initial and re-authorization
based solely on previous claim/medication history, diagnosis codes (ICD-10) and/or claim logic.
Use of automated approval and re-approval processes varies by program and/or therapeutic class.
• Supply limits may be in place.
4. References:
1. Nuplazid [package insert]. San Diego, CA: Acadia Pharmaceuticals Inc.; January 2025.
© 2025 UnitedHealthcare Services, Inc.
1
Program Prior Authorization/Notification – Nuplazid
Change Control
7/2016 New program.
7/2017 Annual review. Updated references.
8/2018 Annual review. Updated references.
12/2018 Administrative change to add statement regarding use of automated
processes.
8/2019 Annual review. Updated references. Clarified that hallucination and
delusion symptoms started after Parkinson’s disease diagnosis.
10/2019 Removed hallucinations requirement to match Diagnosis to Drug
program.
11/2020 Annual review. Updated references.
11/2021 Annual review. Updated references.
12/2022 Annual review. Added state mandate language.
1/2024 Annual review. Updated references. Updated background information.
3/2025 Annual review. Updated references.
© 2025 UnitedHealthcare Services, Inc.
2